DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Summary for Patent: 6,124,448
|Title:||Nucleic acid primers and probes for the mammalian OB gene|
|Abstract:||The present invention relates generally to the control of body weight of animals including mammals and humans, and more particularly to materials identified herein as modulators of weight, and to the diagnostic and therapeutic uses to which such modulators may be put. In its broadest aspect, the present invention relates to the elucidation and discovery of nucleotide sequences, and proteins putatively expressed by such nucleotides or degenerate variations thereof, that demonstrate the ability to participate in the control of mammalian body weight. The nucleotide sequences in object represent the genes corresponding to the murine and human ob gene, that have been postulated to play a critical role in the regulation of body weight and adiposity. Preliminary data, presented herein, suggests that the polypeptide product of the gene in question functions as a hormone. The present invention further provides nucleic acid molecules for use as molecular probes, or as primers for polymerase chain reaction (PCR) amplification, i.e., synthetic or natural oligonucleotides. In further aspects, the present invention provides a cloning vector, which comprises the nucleic acids of the invention; and a bacterial, insect, or a mammalian expression vector, which comprises the nucleic acid molecules of the invention, operatively associated with an expression control sequence. Accordingly, the invention further relates to a bacterial or a mammalian cell transfected or transformed with an appropriate expression vector, and correspondingly, to the use of the above mentioned constructs in the preparation of the modulators of the invention. Also provided are antibodies to the ob polypeptide. Moreover, a method for modulating body weight of a mammal is provided. In specific examples, genes encoding two isoforms of both the murine and human ob polypeptides are provided.|
|Inventor(s):||Friedman; Jeffrey M. (New York, NY), Zhang; Yiying (New York, NY), Proenca; Ricardo (Astoria, NY), Maffei; Margherita (New York, NY)|
|Assignee:||The Rockfeller University (NY)|
|Patent Claims:||1. An isolated nucleic acid of at least 10 nucleotides hybridizable under moderate stringency conditions to a non-coding region of an OB nucleic acid, which non-coding region
is selected from the group consisting of an intron, a 5' non-coding region, and a 3' non-coding region of SEQ ID NOS: 1, 3, 22 or 24.
2. An oligonucleotide primer of at least 10 nucleotides for amplifying mouse or human genomic DNA encoding an OB polypeptide, said primer hybridizable under moderate stringency conditions to any of SEQ ID NOS: 1, 3, 22 or 24.
3. An oligonucleotide according to claim 2 which is selected from the group consisting of:
HOB 1gF 5'-CCCAAGAAGCCCATCCTG-3' (SEQ ID NO. 29);
HOB 1gR 5'-GACTATCTGGGTCCAGTGCC-3' (SEQ ID NO. 30);
HOB 2gF 5'-CCACATGCTGAGCACTTGTT-3' (SEQ ID NO. 31); and
HOB 2gR 5'-CTTCAATCCTGGAGATACCTGG-3' (SEQ ID NO. 32).
4. A detectably labeled nucleic acid molecule of at least 10 nucleotides hybridizable under moderate stringency conditions to a non-coding region of an OB nucleic acid, which non-coding region is selected from the group consisting of an intron, a 5' non-coding region, and a 3' non-coding region of SEQ ID NOS: 1, 3, 22 or 24.
|Applicant||Tradename||Biologic Ingredient||Dosage Form||BLA||Number||Approval Date||Patent No.||Assignee||Estimated Patent Expiration||Status||Orphan||Source|
|Schering||INTRON A||interferon alfa-2b||VIAL||103132||001||1986-06-04||Start Trial||The Rockfeller University (NY)||2017-09-26||RX||search|
|Schering||INTRON A||interferon alfa-2b||VIAL||103132||002||1986-06-04||Start Trial||The Rockfeller University (NY)||2017-09-26||RX||search|
|Schering||INTRON A||interferon alfa-2b||VIAL||103132||003||1986-06-04||Start Trial||The Rockfeller University (NY)||2017-09-26||RX||search|
|>Applicant||>Tradename||>Biologic Ingredient||>Dosage Form||>BLA||>Number||>Approval Date||>Patent No.||>Assignee||>Estimated Patent Expiration||>Status||>Orphan||>Source|
|Country||Patent Number||Publication Date|
|South Africa||9506868||Apr 09, 1996|
|Yugoslavia||54995||May 15, 1998|
|World Intellectual Property Organization (WIPO)||9605309||Feb 22, 1996|
|World Intellectual Property Organization (WIPO)||9605309||Mar 21, 1996|
|United States of America||2002107211||Aug 08, 2002|
|United States of America||2003040039||Feb 27, 2003|
|United States of America||2004213763||Oct 28, 2004|
|>Country||>Patent Number||>Publication Date|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.